Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Seysara for Severe Acne Vulgaris

Paratek Pharmaceuticals, Inc. news release; 2018 Oct 2

Paratek Pharmaceuticals, Inc., has announced that the US Food and Drug Administration (FDA) has approved Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged ≥9 years. Paratek Pharmaceuticals is headquartered in Boston, MA.

Dosage/administration: The recommended dosage of Seysara is once daily with or without food and is based on the patient’s weight:

• 60 mg for patients who weigh 33-54 kg,

• 100 mg for patients who weigh 55-84 kg,

• 150 mg for patients who weigh 85-136 kg.

Adverse effects: The most common adverse reaction (incidence ≥ 1%) is nausea.


FDA approves Seysara (sarecycline) for the treatment of moderate to severe acne. [news release]. Boston, MA: Paratek Pharmaceuticals, Inc. October 2, 2018. Accessed October 18, 2018.